#45 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
Clinicians need to understand the limitations and accuracy of roadside THC testing because patients may face legal consequences based on imperfect screening tools, and patients should know that THC detection does not necessarily correlate with impairment levels. Healthcare providers should be aware of Saskatchewan Government Insurance’s zero-tolerance policy to counsel patients on the legal and insurance implications of cannabis use, regardless of whether they are using it medically or recreationally. This matters for patient safety and liability discussions, as clinicians should inform patients that detection on roadside tests could result in impaired driving charges or insurance penalties even if their driving ability is not compromised.
This article addresses roadside THC testing technology and Saskatchewan Government Insurance’s zero-tolerance cannabis driving policy, topics directly relevant to clinicians counseling patients about cannabis use and impairment. Current roadside testing methods, including oral fluid tests and breathalyzers, have significant limitations in accurately correlating THC detection with actual impairment or driving ability, a critical gap since THC detection does not reliably indicate current impairment the way blood alcohol levels do. Zero-tolerance policies may penalize patients who use cannabis therapeutically or who consumed it hours or days prior when no impairment exists, potentially creating barriers to legitimate medical cannabis access for patients who also drive. Clinicians should be aware that their patients face legal and insurance consequences for cannabis use regardless of timing or medical necessity, which may affect treatment discussions and patient disclosure. Patients on medical cannabis should understand the disconnect between positive roadside tests and actual impairment, and that current driving under the influence laws do not account for this distinction. Clinicians counseling cannabis patients should discuss the legal risks of driving and document medical necessity clearly, while recognizing that current roadside testing and enforcement policies do not reflect the pharmacology of cannabis impairment.
“The fundamental problem with roadside THC testing is that it measures presence, not impairment, yet we’re applying it as though it does—and this gap between what we can detect and what actually matters clinically is costing people their livelihoods. Until we have reliable impairment-based testing, we’re essentially conducting a public health experiment on cannabis users while ignoring the same gap that’s always existed with alcohol and prescription medications.”
💨 Current roadside THC testing technologies remain scientifically limited compared to breath alcohol testing, as THC detection does not reliably correlate with impairment timing or degree, and passive exposure can produce positive results in non-impaired individuals. While zero-tolerance policies provide clear legal standards and may deter some high-risk driving, they do not account for chronic cannabis users who may have detectable THC levels without active impairment, nor do they address the multifactorial nature of driving ability. The evidence base for cannabis impairment testing is still evolving, with significant gaps between what detection methods measure and what actually predicts unsafe driving. Clinicians should be aware that patients taking prescribed or self-medicated cannabis may be subject to legal consequences despite controlled use patterns, and should counsel patients explicitly about cannabis use and driving safety rather than assuming legal policies align with impairment science. When evaluating patients with substance use concerns or motor vehicle
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: